The Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To evaluate therapeutic efficacy and predicting factors of entecavir for treating patients
with acute on chronic hepatitis B liver failure (ACHBLF). A total of 108 patients with ACHBLF
were allocated into either a treatment group (ETV group, n=53) or a control group (n=55). The
HBV DNA level, liver function and survival condition of the patients were observed for 48
weeks after enrollment. The factors possibly related to entecavir treatment efficacy were
also identified.